InflaRx (IFRX) Non-Current Assets (2016 - 2026)
InflaRx (IFRX) posted Non-Current Assets of $1.7 million for Q1 2026, down 5.12% sequentially from $1.8 million in Q4 2025, and up 19.61% YoY from $1.5 million in Q1 2025.
InflaRx (IFRX) Non-Current Assets (2016 - 2026) Analysis & Trends
InflaRx has reported Non-Current Assets for 11 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Non-Current Assets rose 19.61% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.8 million (down 5.87% YoY) and the FY2025 annual result came in at $1.8 million, down 62.15% from the prior year.
- Non-Current Assets fell to $1.7 million in Q1 2026 per IFRX's latest filing, from $1.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $22.6 million in Q2 2023 and troughed at $1.5 million in Q1 2025.
- A 5-year average of $6.0 million and a median of $4.5 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets plunged 93.0% in 2022, then jumped 745.61% in 2023.
- Over 5 years, Non-Current Assets stood at $5.1 million in 2022, then jumped by 127.04% to $11.6 million in 2023, then slumped by 59.66% to $4.7 million in 2024, then plunged by 60.5% to $1.8 million in 2025, then decreased by 5.12% to $1.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.7 million, $1.8 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 6,341.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.75 Mn |
| Dec 31, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 8.23 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 4.66 Mn |
| Sep 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 4.48 Mn |
| Dec 31, 2023 | 11.56 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 22.59 Mn |
| Mar 31, 2023 | 10.63 Mn |
| Dec 31, 2022 | 5.09 Mn |
| Sep 30, 2022 | 2.40 Mn |
| Jun 30, 2022 | 2.67 Mn |
| Mar 31, 2022 | 12.77 Mn |
| Dec 31, 2021 | 33.70 Mn |
| Sep 30, 2021 | 34.34 Mn |
| Jun 30, 2021 | 3.41 Mn |